Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
A phase 2 trial of Durvalumab, Oleclumab, Monalizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05061550 by AstraZeneca, with 630 participants planned, started 2022-04-14 and due to reach its primary completion in 2030-05-28. Interventions recorded: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Shares Monalizumab, Oleclumab, AstraZeneca, Non-small-cell lung cancer.
- TrialA Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Datopotamab deruxtecan, Durvalumab, Cisplatin, AstraZeneca.
- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Datopotamab deruxtecan, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Durvalumab, Cisplatin, AstraZeneca, Carboplatin.
- TrialStudy of AZD2811 + Durvalumab in ES-SCLC
Shares Durvalumab, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C
Shares Datopotamab deruxtecan, Cisplatin, AstraZeneca, Carboplatin.
- TrialStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Shares Durvalumab, Cisplatin, AstraZeneca, Carboplatin.